Paris-based venture capital firm Sofinnova Partners has promoted Javier Nunez-Vicandi to Partner, strengthening its leadership team overseeing investments in digital medicine.
He will join Edward Kliphuis and Simon Turner in the firm’s Digital Medicine strategy, which focuses on companies operating at the intersection of biology, data and artificial intelligence.
Key Contributions to Digital Medicine and AI Investments
Since joining Sofinnova Partners in 2022, Nunez-Vicandi has contributed to the development of its Digital Medicine strategy and wider artificial intelligence initiatives.
He helped establish several of the firm’s key AI investment theses within the strategy and currently serves as a board observer at Latent Labs, Bioptimus, Cure51, Deepc and Kiro.
He has also recently led an investment in a company that has yet to be publicly disclosed.
Beyond the Digital Medicine portfolio, Nunez-Vicandi co-led the development of Sofia, Sofinnova’s proprietary AI platform designed to support investment activities and scientific analysis.
His responsibilities included helping to lead the firm’s collaborations with technology companies AWS and NVIDIA.
Previous Experience in Healthcare and Venture Capital
Before joining Sofinnova, Nunez-Vicandi was the first employee at Heal Capital, an early-stage health technology venture capital fund.
During his time there, he helped build the firm from its launch to a portfolio of 12 investments.
He previously worked as an analyst at M Ventures, where his investment focus covered data-driven healthcare, biotechnology and automation.
Nunez-Vicandi began his professional career in clinical medicine at Oxford University Hospitals NHS Foundation Trust.
His medical experience included positions at the National Spinal Injuries Centre and Churchill Hospital.
Academic Qualifications
Nunez-Vicandi holds a Master of Philosophy degree with distinction from the University of Cambridge.
He also earned a Bachelor of Medicine and Bachelor of Surgery (MBBS) from Newcastle University.
Sofinnova’s Digital Medicine Investment Strategy
Sofinnova Partners’ Digital Medicine strategy covers two main areas of healthcare innovation: healthtech and techbio.
Healthtech investments target businesses using technology to improve healthcare delivery, while techbio focuses on applying artificial intelligence and other computational methods to biological research and drug discovery.
The strategy backs startups developing solutions across these areas, combining advances in technology, data and biological science.
